SCI Pharmtech, Inc. (TPE:4119)

Market Cap	6.76B
Revenue (ttm)	1.55B
Net Income (ttm)	482.50M
Shares Out	119.51M
EPS (ttm)	4.03
PE Ratio	14.04
Forward PE	n/a
Dividend	1.50 (2.60%)
Ex-Dividend Date	Jul 1, 2025

Volume	158,364
Average Volume	136,810
Open	57.60
Previous Close	57.60
Day's Range	56.50 - 57.60
52-Week Range	55.50 - 98.80
Beta	-0.13
RSI	40.68
Earnings Date	Nov 10, 2025

About SCI Pharmtech

SCI Pharmtech, Inc., together with its subsidiary, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals in Italy, the United States, Japan, Germany, Taiwan, Switzerland, China, and internationally. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychloroquine sulfate, loxoprofe...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 239
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 4119

Financial Performance

In 2024, SCI Pharmtech's revenue was 1.52 billion, an increase of 26.54% compared to the previous year's 1.20 billion. Earnings were 534.68 million, an increase of 81.42%.